Persistence of human immunodeficiency virus in semen after adding indinavir to combination antiretroviral therapy

Clinical Infectious Diseases

Volumn 28, Issue 6, 1999, Pages 1252-1259

  Mayer, Kenneth H ^a,b,c   Boswell, Stephen ^a,b,c   Goldstein, Robert ^a,b,c   Lo, Wilson ^a,b,c   Xu, Chong ^a,b,c   Tucker, Lynne ^a,b,c   DePasquale, Maria Pia ^a,b,c   D'Aquila, Richard ^a,b,c   Anderson, Deborah J ^a,b,c  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b MEMORIAL HOSPITAL OF RHODE ISLAND   (United States)

^c BROWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; INDINAVIR; PROTEINASE INHIBITOR;

ARTICLE; DRUG TOLERABILITY; GENITAL SYSTEM; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PERSISTENT VIRUS INFECTION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SEMEN ANALYSIS; VIRUS CONCENTRATION; VIRUS DETECTION; VIRUS INHIBITION; VIRUS LOAD; VIRUS MUTATION; VIRUS SHEDDING; VIRUS TRANSMISSION;

EID: 0033052312     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/514775     Document Type: Article

References (40)

1. 1. Carpenter CCJ, Fischl MA, Hammer S, et al. Antiretroviral therapy for HTV infection in 1997: recommendations of an international panel. JAMA 1997; 277:1962-9.
2. 2. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med 1997; 337:725-33.
3. 3. Centers for Disease Control and Prevention. Update: trends in AIDS incidence-United States, 1996. MMWR Morb Mortal Wkly Rep 1997; 46:861-7.
4. 4. Wong JK, Hezarch M, Gunthard HF, et al. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 1997; 278:1291-4.
5. 5. Finzi D, Hermankova M, Pierson T, et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 1997; 278:1295-9.
6. 6. Ho DD, Schooley RT, Rota TR, et al. HTLV-III in the semen and blood of a healthy homosexual man. Science 1984; 226:451-3.
7. 7. Krieger JN, Coombs RW, Collier AS, et al. Recovery of human immunodeficiency virus type 1 from semen: minimal impact of stage of infection and current antiretroviral chemotherapy. J Infect Dis 1991; 163:386.
8. 8. Van Voorhis BJ, Martinez A, Mayer KH, Anderson DJ. Detection of human immunodeficiency virus type 1 in semen from seropositive men using culture and polymerase chain reaction deoxynbonucleic acid amplification techniques. Fertil Steril 1991; 55:588-94.
9. 9. Vernazza PL, Eron JJ, Cohen MS, van der Horst CM, Troigi L, Fiscus SA. Detection and biological characterization of infectious HIV-1 in semen of seropositive men. AIDS 1994; 8:1325-9.
10. 10. Mermin JH, Holodniy M, Katzenstein DA, Merigan TC. Detection of human immunodeficiency virus DNA and RNA in semen by the polymerase chain reaction. J Infect Dis 1991; 164:769-72.
11. 11. Quayle AJ, Xu C, Mayer KH, Anderson DJ. T lymphocytes and macrophages, but not motile spermatozoa, are a significant source of HIV in semen. J Infect Dis 1997; 176:960-8.
12. 12. Hecht FM, Grant RM, Petropoulos CJ, et al. Transmission of HIV-1 resistant to multiple reverse transcriptase and protease inhibitors. N Engl J Med 1998; 339:307-11.
13. 13. Kakuda TN, Struble KA, Piscitelli SC. Protease inhibitors for the treatment of human immunodeficiency virus infection. Am J Health Syst Pharm 1998; 55:233-54.
14. 14. Deeks SG, Smith M, Holodniy M, Kahn JO. HIV-1 protease inhibitors. A review for clinicians. JAMA 1997; 227:145-53.
15. 15. Hamed K, Winters MA, Holodniy M, Katzenstein DA, Merigan TC. Detection of human immunodeficiency virus type 1 in semen: effects of disease stage and nucleoside therapy. J Infect Dis 1993; 167:798-802.
16. 16. Anderson DJ, O'Brien TR, Politch JA, et al. Effects of disease stage and zidovudine therapy on the detection of human immunodeficiency virus type 1 in semen. JAMA 1992; 267:2769-74.
17. 17. Gilliam BL, Dyer JR, Ficus SA, et al. Effects of reverse transcriptase inhibitor therapy on the HIV-1 viral burden in semen. J Acquir Immune Defic Syndr Hum Retrovirol 1997; 15:54-60.
18. 18. Gupta P, Mellors J, Kingsley L, et al. High viral load in semen of human immunodeficiency virus type 1 infected men at all stages of disease and its reduction by therapy with protease and nonnucleoside reverse transcriptase inhibitors. J Virol 1997; 71:1-5.
19. 19. Imrie A, Beceridge A, Genn W, Vizzard J, Cooper DA. Transmission of human immunodeficiency virus type 1 resistant to nevirapine and zidovudine. Sydney Primary HIV Infection Study Group. J Infect Dis 1997; 175:1502-6.
20. 20. Angarano G, Monno L, Appice A. Transmission of zidovudine-resistant HIV-1 through heterosexual contacts [letter]. AIDS 1994; 8:1013-4.
21. 21. Conlon CP, Klenerman P, Edwards A, Larder BA, Phillips RE. Heterosexual transmission of human immunodeficiency virus type 1 variants associated with zidovudine resistance. J Infect Dis 1994; 169:411-5.
22. 22. Erice A, Mayers DL, Strike DG. Brief report: primary infection with zidovudine-resistant human immunodeficiency virus type 1. N Engl J Med 1993; 328:1163-5.
23. 23. Martinez-Picado J, Sutton L, Hoes Helfant A, Savara A, Kaplan J, D'Aquila RT. Novel clonal analyses of resistance to HIV-1 RT and protease inhibitors [abstract no 45]. Antiviral Therapy 1997; 2 (suppl):30.
24. 24. Ratner L, Fischer A, Jagodzinski L, et al. Complete nucleoside sequences of functional clones of the AIDS virus. AIDS Res Hum Retroviruses 1987; 3:59-69.
25. 25. Mellors JW, Kingsley LA, Rinaldo CR, Hoo BS, Kokka RP, Gupta P. Quantitation of HIV-1 RNA in plasma predicts outcome after serocon-version. Ann Intern Med 1995; 112:573-9.
26. 26. Glantz SA, ed. Primer of biostatistics. 1st ed. New York: McGraw-Hill, 1981.
27. 27. Condra JH, Holder DJ, Schleif WA, Blahy OM, Danovich RM, Gabryelski LJ. Genetic correlates of in-vitro viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor. J Virol 1996; 70: 8270-6.
28. 28. Gulick RM, Mellors JW, Havlir D, et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection und prior antiretroviral therapy. N Engl J Med 1997; 337: 734-9.
29. 29. Vernazza PL, Gilliam BL, Dyer JR. Quantification of HIV in semen: correlation with antiviral treatment and immune status. AIDS 1997; 11: 987-93.
30. 30. Cohen MS, Huffman IF, Royce RA. Reduction of concentration of HIV-1 in semen after treatment of urethritis: implications for prevention of sexual transmission of HIV-1. Lancet 1997; 349:1868-73.
31. 31. Celum CL, Buchbinder SP, Mayer KH, et al. Characteristics of new seroconverters and their predominant viral type. In: Conference record of the 12th World AIDS Conference. Geneva: Marathon Multimedia, 1998.
32. 32. Zhu T, Wang N, Carr A. Genetic characterization of human immunodeficiency virus type 1 on blood and genital secretions: evidence for viral compartmentalization and selection during sexual transmission. J Virol 1996; 70:3098-107.
33. 33. Wolff H, Anderson DJ. Immunohistologic characterization and quantitation of leukocyte subpopulations in human semen. Fertil Steril 1988; 49:497-504.
34. 34. Eron JJ, Vernazza PL, Johnston DM, et al. Resistance of HIV-1 to antiretroviral agents in blood and seminal plasma: implications for transmission, AIDS 1998; 12:F181-9.
35. 35. Patick AK, Mo H, Markowitz M, et al. Antiviral and resistance studies of AG1343, an orally bioavailable inhibitor of human immunodeficiency virus protease. Antimicrob Agents Chemother 1996; 40:292-7.
36. 36. Martinez-Picado J, Savaro A, Sutton L, D'Aquila RT. Replicative fitness of protease inhibitor resistant mutants of human immunodeficiency virus type 1. J Virol 1999; 73:3744-52.
37. 37. Nijhuis M, Schuurman R, de Jong D, Schipper P, Danner S, Boucher C. Selection of HIV-1 variants with increased fitness during ritonavir therapy [abstract no 92]. Antiviral Therapy 1997; 2(suppl):87-8.
38. 38. Girard ML, Rimsky L, Manhoney J, et al. Transmission of HIV-1 by the mucosal route in female chimpanzees [abstract no 9]. In: AIDS II London: Lippincott, Williams and Wilkins, 1993.
39. 39. Centers for Disease Control and Prevention. Gonorrhea among men who have sex with men - selected sexually transmitted diseases clinics, 1993-1996. MMWR Morb Mortal Wkly Rep 1997; 46:889-92.
40. 40. Division of STD Prevention, National Center for HIV, STD, and TB Prevention. Sexually transmitted disease surveillance, 1995. Atlanta: U.S. Department of Health & Human Services, Public Health Service, Centers for Disease Control and Prevention, 1996.